First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.

Planchard D., Cho B. C., Gray J. E., Paz-Ares L. G., Ozguroglu M., Villegas A. E., ...More

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Volume: 37
• City: Illinois
• Country: United States Of America
• Istanbul University-Cerrahpasa Affiliated: No